Role of phenytoin in wound healing - A wound pharmacology perspective

Biochemical Pharmacology

Volumn 57, Issue 10, 1999, Pages 1085-1094

  Talas, Györgyi ^a   Brown, Robert A ^a   McGrouther, D Angus ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cytochromes P450; Gingival hyperplasia; Phenytoin; Wound healing

Indexed keywords

CYTOCHROME P450; PHENYTOIN; PHENYTOIN DERIVATIVE;

ANIMAL EXPERIMENT; CLINICAL TRIAL; CONVULSION; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; GINGIVA HYPERPLASIA; HUMAN; NONHUMAN; NOTE; ORAL DRUG ADMINISTRATION; PERIODONTITIS; PRIORITY JOURNAL; SKIN; TOPICAL DRUG ADMINISTRATION; WOUND HEALING; XENOBIOTIC METABOLISM;

ADMINISTRATION, TOPICAL; ANTICONVULSANTS; FORECASTING; GINGIVAL HYPERPLASIA; HUMANS; PHENYTOIN; WOUND HEALING;

EID: 0033562791     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00363-3     Document Type: Note

References (71)

1. Majno G, The Healing Hand: Man and Wound in the Ancient World. Harvard University Press, Cambridge, MA, 1975.
2. Martin P, Wound healing - Aiming for perfect skin regeneration. Science 276: 75-81, 1997.
3. Arnold F, Cherry G, Cox D, Hutchinson G and Weston-Davies W, Wound pharmacology: A report from the wound pharmacology forum. Wound Rep Reg 4: 121-126, 1996.
4. Penarrocha-Diago M, Bagan-Sebastian JV and Vera-Sempere F, Diphenylhydantoin-induced gingival overgrowth in man: A clinico-pathological study. J Periodontol 61: 571-574, 1990.
5. Yaari Y, Selzer ME and Pincus JH, Phenytoin: Mechanisms of its anticonvulsant action. Ann Neural 20: 171-184, 1986.
6. Barnhart ER, Physician's Desk Reference, 51st Edn. Medical Economics Co., Oradell, NJ, 1997.
7. Woodbury DM, Phenytoin absorption, distribution, and excretion. In: Antiepileptic Drugs (Eds. Levy RH, Dreifuss FE, Mattson RH, Meldrum BS, Penry JK and Hessie BJ), 3rd Edn, pp. 177-196. Raven Press, New York, 1989.
8. Browne TR and Chang T, Phenytoin biotransformation. In: Antiepileptic Drugs (Eds. Levy RH, Dreifuss FE, Mattson RH, Meldrum BS, Penry JK and Hessie BJ), 3rd Edn, pp. 197-213. Raven Press, New York, 1989.
9. Dudley KH, Phenytoin metabolism. In: Phenytoin-induced Teratology and Gingival Pathology (Eds. Hassell TM, Johnston MC and Dudley KH), pp. 13-24. Raven Press, New York, 1980.
10. Doecker CJ, Sansom LN and McManus ME, Phenytoin 4-hydroxylation by rabbit liver P450IIC3 and identification of orthologs in human liver microsomes. Biochem Biophys Res Commun 166: 860-866, 1990.
11. Ieiri I, Goto W, Toshitani A, Imayama S, Ohyama Y, Yamada H, Ohtsubo K and Higuchi S, Effect of 5-(p-hydroxyphenyl)-5-phenylhydantoin (p-HPPH) enantiomers, major metabolites of phenytoin, on the occurrence of chronic, gingival hyperplasia: In vivo and in vitro study. Eur J Clin Pharmacol 49: 51-56, 1995.
12. Hassell TM, Page RC and Lindhe J, Histologie evidence for impaired growth control in diphenylhydantoin gingival overgrowth in man. Arch Oral Biol 23: 381-384, 1978.
13. Dill RE and Iacopino AM, Myofibroblasts in phenytoin-induced hyperplastic connective tissue in the rat and in human gingival overgrowth. J Periodontol 68: 375-380, 1997.
14. Erlich HP, Desmouliere A, Diegelmann RF, Cohen IK, Compton CC, Garner WL, Kapanci Y and Gabbiani G, Morphological and immunochemical differences between keloid and hypertrophie scar. Am J Pathol 145: 105-113, 1994.
15. Bartold PM, Turnover in periodontal connective tissues: Dynamic homeostasis of cells, collagen and ground substances. Oral Dis 1: 238-253, 1995.
16. Sempowski GD, Borello M, Blieden TM, Barth RK and Phipps RP, Fibroblast heterogeneity in the healing wound. Wound Rep Reg 3: 121-131, 1995.
17. Conard GJ, Jeffay H, Boshes J and Steinberg AD, Levels of 5,5-diphenylhydantoin and its major metabolite in human serum, saliva and hyperplastic gingiva. J Dent Res 53: 1323- 1329, 1974.
18. Steinberg AD, Phenytoin penetration through sulcular tissue and its possible relationship to phenytoin-induced gingival overgrowth. In: Phenytoin-induced Teratology and Gingival Pathology (Eds. Hassell TM, Johnston MC and Dudley KH), pp. 179-187. Raven Press, New York, 1980.
19. Rao GS and Wortel JP, Gingival metabolism of phenytoin and covalent binding of its reactive metabolite to gingival proteins in the rat. In: Phenytoin-induced Teratology and Gingival Pathology (Eds. Hassell TM, Johnston MC and Dudley KH), pp. 189-198. Raven Press, New York, 1980.
20. Zhou LX, Pilhstrom B, Hardwick JP, Park SS, Wrighton SA and Holtzman JI, Metabolism of phenytoin by the gingiva of normal humans: The possible role of reactive metabolites of phenytoin in the initiation of gingival hyperplasia. Clin Pharmacol Ther 60: 191-198, 1996.
21. Bickers DR, Mukhtar H, Meyer LW and Speck WT, Epidermal-enzyme mediated mutagenicity of the skin carcinogen 2-aminoanthracene. Mutat Res 147: 37-43, 1985.
22. Baron J, Voigt JM, Whitter TB, Kawabata TT, Knapp SA and Guengerich FP, Localisation of carcinogen-metabolising enzymes in human and animal tissues. In: Extrahepatic Drug Metabolism and Chemical Carcinogenesis (Eds. Rydstrom I, Montelius J and Bengtsson M), pp. 73-89. Elsevier, Amsterdam, 1983.
23. 3H]PbTx-3 (a red tide toxin) through monkey buccal mucosa and skin. Toxicol Lett 55: 185-194, 1991.
24. Brown RS, Beaver WT and Bottomley WK, On the mechanism of drug-induced gingival hyperplasia. J Oral Pathol Med 20: 201-209, 1991.
25. Kinane DF, Drummond JR and Chisholm DM, Langerhans cells in human chronic gingivitis and phenytoin-induced gingival hyperplasia. Arch Oral Biol 35: 561-564, 1990.
26. Brunius G, Iinuma M, Andruén I, Lerner UH and Modéer T, The phenytoin metabolite p-HPPH upregulates prostaglandin biosynthesis in human gingival fibroblasts challenged to interleukin-1. Life Sci 53: 503-515, 1993.
27. Benveniste K and Bitar M, Effects of phenytoin on cultured human gingival fibroblasts. In: Phenytoin-induced Teratology and Gingival Pathology (Eds. Hassell TM, Johnston MC and Dudley KH), pp. 199-213. Raven Press, New York, 1980.
28. Hassell TM and Gilbert GH, Phenytoin sensitivity of fibroblasts as the basis for susceptibility to gingival enlargement. Am J Pathol 112: 218-223, 1983.
29. Hassel TM and Stanek E III, Evidence that healthy human gingiva contains functionally heterogeneous fibroblast subpopulations. Arch Oral Biol 23: 617-625, 1983.
30. Martin GM, Sprague CA, Norwood TH and Pendergrass WH, Clonal selection, attenuation and differentiation in an in vitro model of hyperplasia. Am J Pathol 74: 137-154, 1974.
31. Eastwood M, Porter R, Khan U, McGrouther DA and Brown R, Quantitative analysis of collagen gel contractile forces generated by dermal fibroblasts and the relationship to cell morphology. J Cell Physiol 166: 33-42, 1996.
32. Shapiro M, Acceleration of gingival wound healing in non-epileptic patients receiving Diphenylhydantoin (Dilantin, Epanutin). Exp Med Surg 16: 41-53, 1958.
33. Chikhani P, Utilisation de la phenytoine sodique dans le traitement des paradontopathies. Actual Odontostomatol (ParIs) 26: 265-274, 1972.
34. Goebel RW, Sodium diphenylhydantoin association with oral healing. J Oral Surg 30: 191-195, 1972.
35. Savini EC, Poitevin R and Payen J, Topical application of hydantoins in gingival disorders. In: Phenytoin-induced Teratology and Gingival Pathology (Eds. Hassell TM, Johnston MC and Dudley KH), pp. 215-225. Raven Press, New York, 1980.
36. Bogaert H, Saleta B, Sanchez E and Garcia B, Trophic leprosy ulcers: Treatment with topical and systemic phenytoin. Int J Dermatol 29: 156-157, 1990.
37. Malhotra YK and Amin SS, Role of topical phenytoin in trophic ulcers of leprosy in India. Int J Lepr Other Mycobact Dis 59: 337-338, 1991.
38. Menezes J, Rajendran A, Jacob AJW and Vaz M, The use of topical phenytoin as an adjunct to immobilization in the treatment of trophic leprosy ulcers. Southeast Asian J Trop Med Public Health 24: 340-342, 1993.
39. Bansal NK and Mukul, Comparison of topical phenytoin with normal saline in the treatment of chronic trophic ulcers in leprosy. Int J Dermatol 32: 210-213, 1993.
40. Rodriguez-Noriega E, Esparza Ahumada S, Andrade-Perez JS, Espejo-Plascencia I and Chapa-Alvarez JR, Tratamiento de ulceraciones en tejidos blandos con definilhidantoinato topico. Invest Med Int 10: 184-186, 1983.
41. Modaghegh S, Salehian B, Tavassoli M, Djamshidi A and Rezai AS, Use of phenytoin in healing of war and non-war wounds: A pilot study of 25 cases. Int J Dermatol 28: 347-350, 1989.
42. el Zayat S, Preliminary experience with topical phenytoin in wound healing in a war zone. Milit Med 154: 178-180, 1989.
43. Anstead GM, Hart LM, Sunahara JF and Liter ME, Phenytoin in wound healing. Ann Pharmacother 30: 768-775, 1996.
44. Muthukumarasamy MG, Sivakumar G and Manoharan G, Topical phenytoin in diabetic foot ulcers. Diabetes Care 14: 909-911, 1991.
45. Pendse AK, Sharma A, Sodani A and Hada S, Topical phenytoin in wound healing. Int J Dermatol 32: 214-217, 1993.
46. Lodha SC, Lohiya ML, Vyas MCR, Bhandari S, Goyal RR and Harsh MK, Role of phenytoin in healing of large abscess cavities. Br J Surg 78: 105-108, 1991.
47. Flanagan PM and Flanagan AM, Phenytoin and wound healing. Trop Doct 22: 172, 1992.
48. Mendiola-Gonzales JF, Espejo-Polascencia I, Chapa-Alvarez JR and Rodriguez-Noriega E, Sodium diphenylhydantoin in burns; effects on pain and healing. Invest Med Int 10: 449-451, 1983.
49. Smith BH, Moore M and Jain K, The first international conference on the uses of phenytoin in dermatology. Int J Dermatol 27: 528-530, 1988.
50. Lodha SC, New application of an old drug: Topical phenytoin for burns. J Burn Care Rehabil 12: 96, 1991.
51. Yadav JK, Singhvi AM, Kumar N and Garg S, Topical phenytoin in the treatment of split-thickness skin autograft donor sites: A comparative study with polyurethane membrane drape and conventional dressing. Burns 19: 306-310, 1993.
52. Masgrau-Peya E, Lacour M and Salomon D, Topical phenytoin accelerates healing in epidermolysis bullosa simplex. Dermatology 190: 254, 1995.
53. Cheng PTH and Staple PH, Effect of a dorsal dermal surgical wound on the chemical response of rat abdominal skin to chrome administration of sodium diphenylhydantoin. J Dent Res 51: 131-143, 1972.
54. Bauer EA, Cooper TW and Tucker DR, Phenytoin therapy of recessive dystrophic epidermolysis bullosa. Clinical trial and proposed mechanism of action on collagenase. N Engl J Med 303: 776-781, 1980.
55. Pierce GF and Mustoe TA, Pharmacologie enhancement of wound healing. Annu Rev Med 46: 467-481, 1995.
56. Lewis WG and Rhodes RS, Systemic absorption of topical phenytoin sodium. Ann Pharmacother 28: 961, 1994.
57. Walker M, Hulme TA, Rippon MG, Walmsley RS, Gunnigle S, Levin M and Winsey S, In vitro models for the percutaneous delivery of active tissue repair agents. J Pharm Sci 86: 1379-1384, 1997.
58. Streinstrasser I and Merkle HP, Dermal metabolism of topically applied drugs: Pathways and models considered. Pharm Acta Helv 70: 3-24, 1995.
59. Clark RAF (Ed.), The Molecular. and Cellular Biology of Wound Repair, 2nd Edn. Plenum Press, New York, 1996.
60. Moy LS, Tan EML, Holness R and Uitto J, Phenytoin modulates connective tissue metabolism and cell proliferation in human skin fibroblast cultures. Arch Dermatol 121: 79-83, 1985.
61. Genever PG, Cunliffe WJ and Wood EJ, Influence of the extracellular matrix on fibroblast responsiveness to phenytoin using in vitro wound healing models. Br J Dermatol 133: 231-235, 1995.
62. Dill RE, Miller EK, Weil T, Lesley S, Farmer GR and Lacopino AM, Phenytoin increases gene expression for platelet-derived growth factor B chain in macrophages and monocytes. J Periodontol 64: 169-173, 1993.
63. Talas G, Porter R, Rubio G and Brown RA, Analysis of Phenytoin stimulation of human dermal fibroblast activity. Wound Rep Reg 2: 226, 1994.
64. Bonnaure-Mallet M, Tricot-Doleux S and Godeau GJ, Changes in extracellular matrix macromolecules in human gingiva after treatment with drugs inducing gingival overgrowth. Arch Oral Biol 40: 393-400, 1995.
65. Hobson MI, Brown RA, Green CJ and Terenghi G, Inter-relationships between angiogenesis and nerve regeneration: A histochemical study. Br J Plast Surg 50: 125-131, 1997.
66. Camay L and Grundfest S, Excitable membrane stabilization by diphenylhydantoin and calcium. Neuropharmacology 13: 1097-1108, 1974.
67. Smith BH, Bogoch S and Dreyfus J, The Broad Range of Clinical Use of Phenytoin: Bioelectric Modulator: Bibliography and Review. Dreyfus Medical Foundation, New York, 1988.
68. Adams LW and Priestley GC, Collagen lattices contracted by skin fibroblasts: Drug-induced changes. Arch Dermatol Res 280: 114-118, 1988.
69. Talas G, Adams TST, Eastwood M, Rubio G and Brown RA, Phenytoin reduces the contraction of recessive dystrophic epidermolysis bullosa fibroblast populated collagen gels. Int J Biochem Cell Biol 29: 261-270, 1997.
70. Talas G, Adams TST, Porter RA, Eastwood M and Brown RA, Phenytoin alters dermal fibroblast contraction in vitro and wound contraction in vivo. Wound Rep Reg 4: A177, 1994.
71. Harding K, The future of wound healing. In: Wounds: Biology and Management (Eds. Leaper DJ and Harding KG), pp. 191-192. Oxford University Press, New York, 1998.